ENLV Enlivex Ltd Forecast, Technical & Fundamental Analysis
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis... Show more
ENLV is expected to report earnings to -30 cents per share on August 24
Q2'26
Est.
$-0.30
Q1'26
Beat
by $0.86
Q4'25
Est.
$-0.14
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.04
The last earnings report on May 22 showed earnings per share of -30 cents, beating the estimate of -115 cents. With 74.84K shares outstanding, the current market capitalization sits at 25.70M.
A.I. Advisor
published General Information
General Information
a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions
A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.
ENLV sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ENLV moved below the 200-day moving average on August 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for ENLV crossed bearishly below the 50-day moving average on July 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ENLV entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ENLV just turned positive on August 10, 2026. Looking at past instances where ENLV's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .
ENLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.013) is normal, around the industry mean (20.145). P/E Ratio (0.004) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
